DARA BioSciences Inc

Type: Company
Name: DARA BioSciences Inc
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

LHS Helps DARA BioSciences Launch Patient Smartphone App, Gain Targeted Media Coverage

Opportunity: DARA BioSciences launched a smartphone app to provide cancer patients an educational resource to help patients diagnosed with cancer improve oral care and management of oral mucositis in support of Gelclair®, a bioadherent oral rinse ge ... [Published LaVoie Group - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

5 Stocks Under $10 Set to Soar Higher

DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share or less don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline ... [Published The Street Latest - Jul 07 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Biotech Stocks Technical Analysis -- Research on Mast Therapeutics, Sangamo BioSciences, DARA Biosciences, and Idera Pharma

/PRNewswire/ --On Monday, June 30, 2014, the NASDAQ Composite ended at 4,408.18, up 0.23%, the Dow Jones Industrial Average finished the day 0.15% lower at 16,826.60, and the S&P 500 closed at 1,960.23, down 0.04%. During the session five out of ten sectors ... [Published Nasdaq - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

DARA BioSciences' KRN5500 Secures FDA Orphan Drug Designation for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma.In its release, the Company noted:KRN5500 is a novel, intravenous, non-opioid, ... [Published HighBeam Research - Jun 27 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 2 reports

DARA BioSciences: KRN5500 Secures Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma.According to a release, KRN5500 is a novel, intravenous, non-opioid, ... [Published HighBeam Research - Jun 24 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

DARA BioSciences: KRN5500 Gets Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma.According to a release, KRN5500 is a novel, intravenous, non-opioid, ... [Published HighBeam Research - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Is DARA BioSciences' Rebound Sustainable?

10:36 AM| about stocks: DARADARA BioSciences, Inc. (NASDAQ: DARA ) is a Raleigh, North Carolina-based pharmaceutical company specializing in supportive oncology care. The company manufactures and sells a portfolio of drugs for preventive care and treatment ... [Published Seeking Alpha - Jun 19 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix

PR NewswireNEW YORK, June 19, 2014NEW YORKToday, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix ... [Published Digital Journal - Jun 19 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

DARA BioSciences: KRN5500 Gets Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma. According to a release, KRN5500 is a novel, intravenous, non-opioid, ... [Published Individual.com - Jun 19 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 6 reports

Update: DARA BioSciences shuffles its top management

Updated Jun. 17, 2014 at 3:21 p.m. DARA BioSciences shuffles its top management DARA Related Blog Posts Site SearchBy WRAL TechWireRaleigh, N.C. — Dr. David Drutz, an MD., is now the executive chairman of the board, and Christopher Clement takes ... [Published Local Tech Wire - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 8 reports

DARA BioSciences Rating Reiterated by Zacks (DARA)

DARA BioSciences (NASDAQ:DARA)Zacks’ analyst wrote, " On June 16, 2014, DARA BioSciences, Inc. (DARA) announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to KRN5500 for the treatment of multiple myeloma ... [Published American Banking News - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Healthcare review: Regulus Therapeutics, Affymax, Parexel, Dara Biosciences, CymaBay Therapeutics

:22 US stocks fluctuated, after equities posted their first weekly drop in a month, as investors weighed escalating tension in Iraq against deals and data showing a faster-than-forecast rise in industrial output.The Standard & Poor’s 500 was little ... [Published BioMedReports - Jun 16 2014]

Quotes

Dr. Drutz continued, "We greatly appreciate the expeditious review and approval of this additional KRN5500 orphan designation application by the FDA's Office of Orphan Product Development, which provides an important step towards the potential treatment of multiple myeloma and one of its major complications. This second orphan drug designation underscores the value of this asset and strengthens DARA's resolve and positioning in the ongoing pursuit of partnering opportunities to assist in funding the clinical advancement and development pathway of KRN5500."
"This second orphan drug designation underscores the value of this asset and strengthens DARA's resolve and positioning in the ongoing pursuit of partnering opportunities to assist in funding the clinical advancement and development pathway of KRN5500" Drutz added
...Authors from MGH conclude, "There were no objective responses, although 3 of 17 evaluable patients exhibited disease stabilization for 5-6 cycles" (Supko et al., 2003)
"In these roles, Dr. Drutz will provide ongoing leadership to DARA's strategic planning, business development and educational product support activities relative to our customers and sales organization" DARA said in a statement

More Content

All (72) | News (49) | Reports (0) | Blogs (21) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
LHS Helps DARA BioSciences Launch Patient Smart... [Published LaVoie Group - Jul 08 2014]
5 Stocks Under $10 Set to Soar Higher [Published The Street Latest - Jul 07 2014]
Biotech Stocks Technical Analysis -- Research o... [Published Nasdaq - Jul 01 2014]
DARA BioSciences' KRN5500 Secures FDA Orphan Dr... [Published HighBeam Research - Jun 27 2014]
DARA BioSciences: KRN5500 Secures Orphan Drug D... [Published HighBeam Research - Jun 24 2014]
DARA BioSciences: KRN5500 Secures FDA Orphan Dr... [Published Pharmacy Choice - Jun 24 2014]
Your 56 WRAL TechWire headlines from last week [Published Local Tech Wire - Jun 23 2014]
DARA BioSciences: KRN5500 Gets Orphan Drug Desi... [Published HighBeam Research - Jun 20 2014]
Is DARA BioSciences' Rebound Sustainable? [Published Seeking Alpha - Jun 19 2014]
Agreements, Orphan Drug Designations, and Manag... [Published Digital Journal - Jun 19 2014]
Agreements, Orphan Drug Designations, and Manag... [Published Financial Services - Jun 19 2014]
DARA BioSciences: KRN5500 Gets Orphan Drug Desi... [Published Individual.com - Jun 19 2014]
DARA BioSciences receives FDA orphan drug desig... [Published Pharmaceutical Technology - Jun 18 2014]
Today In SA PRO [Published Seeking Alpha - Jun 18 2014]
DARA Snags Second Orphan Indication For KRN5500 [Published BioPortfolio - Jun 18 2014]
DARA Snags Second Orphan Indication For KRN5500 [Published Seeking Alpha - Jun 18 2014]
Update: DARA BioSciences shuffles its top manag... [Published Local Tech Wire - Jun 17 2014]
Multiple Myeloma Compound Gets Orphan Drug Status [Published American Journal of Public Health - Jun 17 2014]
Raleigh's Dara Bio shuffles up C-suite [Published Business First of Buffalo - Jun 17 2014]
Leadership changes at DARA [Published Seeking Alpha - Jun 17 2014]
DARA BioSciences Promotes Christopher Clement T... [Published RTTNews.com - Jun 17 2014]
DARA BioSciences Announces Leadership Transition [Published BusinessWeek - Jun 17 2014]
DARA BioSciences Announces Leadership Transition [Published MarketWired - Jun 17 2014]
DARA BioSciences Announces Leadership Transition [Published TVNewsCheck - Jun 17 2014]
DARA BioSciences Announces Leadership Transition [Published Marketwire - Breaking News Releases - Jun 17 2014]
DARA BioSciences Rating Reiterated by Zacks (DARA) [Published American Banking News - Jun 17 2014]
Trimel to Present at the 2014 Bloom Burton Co. ... [Published BioMedReports - Jun 16 2014]
Healthcare review: Regulus Therapeutics, Affyma... [Published BioMedReports - Jun 16 2014]
Markets rise as home builder sentiment advances [Published EMoneyDaily - Jun 16 2014]
Dara stock surges after an experimental drug ge... [Published Triangle Business Journal - Jun 16 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DARA BioSciences Announces Leadership Transition [Published Marketwire - Breaking News Releases - Jun 17 2014]
Current President and COO Christopher G. Clement Named CEO; David J. Drutz, MD Transitions to Executive Chairman and Retains CMO Role; Haywood D. Cochrane, Jr. Assumes Role of Vice Chairman ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Technology News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Photo/Multimedia News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Health News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire News with Multimedia - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Agreements, Orphan Drug Designations, and Manag... [Published Financial Services - Jun 19 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.